

Registration  
for the Advanced Training Course in  
**Gene Technology, Biosafety and Biosecurity**  
at Hannover Medical School

Each applicant should complete a separate form.

Please write in **CAPITAL LETTERS**.

Mr.                       Ms.

Name, Title.....

First Name.....

University/Company.....

Institute/Department.....

Street.....

Postcode ..... City.....

Phone.....

Fax.....

E-Mail.....

I am an employee of the MHH – OE ....

I am enrolled in the PhD-program of the MHH

I will transfer the registration fee of € 510 / € 255  
to:

**MHH**

**Sparkasse Hannover**

**IBAN: DE15 2505 0180 0000 3703 71**

**BIC: SPKHDE2HXXX**

**Reference:**

**Your Name/Institution-OE 0014-Fonds 19572000**

by September 16<sup>th</sup>, 2022

.....  
Place, Date

.....  
Signature

**Organisation**

Dr. J. Mertsching, Biosafety Officer

**Registration Fee**

€ 510

Participants from universities and other areas of public service pay a reduced fee of € 255.

Hannover Medical School will cover the cost of participation for its own employees.

**Enrolment**

To enrol for the course, please send your completed application form (full last name, title and first name) to

Hannover Medical School (MHH)

Andrea Leman

Biosafety, OE 0014

30623 Hannover

Phone: +49-511-532-5580

Fax: +49-511-532-8580

E-Mail: leman.andrea@mh-hannover.de

Deadline for receipt of applications is **Sept. 09th, 2022**.

The registration is binding and will be confirmed in writing.

**Venue**

Hannover Medical School

Building J6, Lecture Hall R

Carl-Neuberg-Straße 1

30625 Hannover

Site plan:

<https://www.mhh.de/en/map-of-the-mhh>

**Date: September 27<sup>th</sup>-28<sup>th</sup>, 2022**

**Please note: The organisers reserve the right to alter:**

- Time schedule
- Speakers
- Form of training: Online course (by MS Teams) instead of on-site (due to pandemic situation)

MHH

Medizinische Hochschule  
Hannover



State-approved Course § 28 GenTSV  
for Project Leaders and Biosafety Officers

# Gene Technology, Biosafety and Biosecurity

September 27<sup>th</sup>-28<sup>th</sup>, 2022

Under the German Genetic Engineering Act project leaders and biosafety officers must complete a supplementary training with emphasis on risk assessment, safety measures, principles of legislation and workers' protection. The content is based on the curriculum of the Federal Biotechnology Authority with viral vector systems, transgenic animal models and the European Genetic Engineering Directive as additional areas of focus.

This course is directed at life scientists and medical doctors, in particular English-speaking scientists, who as project leaders or biosafety officers will be responsible for the conduct of genetic engineering experiments in Germany.

**Program**

**Venue: Lecture Hall R, Building J 6**

Tuesday, September 27<sup>th</sup>

- 08.00-08.45**     **Registration**
- 08.50**            **J. MERTSCHING (Chairman)**  
Welcome and Introduction
- 09.00-10.30**    **A. KLOS**  
Safety aspects and risk assessment for dealing with bacteria and parasites in gene technology
- 10.30-10.45      Coffee Break
- 10.45-12.15**    **J. BOHNE**  
Safety aspects and risk assessment for dealing with viruses and cell culture in gene technology
- 12.15-13.15     Lunch Break
- 13.15-14.45**    **A. SEIFFERT-STÖRIKO**  
Technical safety measures for designated genetic engineering areas
- 14.45-15.00     Coffee Break
- 15.00-15.45**    **J. BOCH**  
Utilization and endangering potentials of transgenic plants; environmental considerations in a deliberate release
- 15.45-16.45**    **A. BLEICH**  
Working with and potential of transgenic animal models

**Speakers:**

**Prof. André Bleich, PhD**

Institute for Laboratory Animal Science, MHH

**Prof. Dr. rer. nat. Jens Boch**

Institute of Plant Genetics, University of Hannover

**PD Dr. rer. nat. Jens Bohne**

Institute of Virology, MHH

**Dipl.-Biol. Stefan Gerstel**

Dept. of Biosafety, MHH

Wednesday, September 28<sup>th</sup>

- 09.00-10.00**    **J. BOHNE**  
Viral vectors and genome editing - Risk assessment
- 10.00-10.45**    **S. GERSTEL**  
Transport and shipping of biological material
- 10.45-11.00      Coffee Break
- 11.00-12.30**    **J. KAHRMANN**  
Genetic Engineering Law - Regulations for the application of gene technology
- 12.30-13.30     Lunch Break
- 13.30-15.00**    **M. KASPARI**  
Safety classification of genetic engineering projects
- 15.00-15.15     Coffee Break
- 15.15-16.45**    **J. MERTSCHING**  
Biorisk Management - Notification, registration and authorization BioStoffV - Impact on genetic engineering
- 16.45-17.00**    **J. MERTSCHING**  
Final discussion

**Jens Kahrmann**

Legal Officer, Berlin

**Dr. rer. nat. Marion Kaspari**

Scientific Officer for Biosafety, Berlin

**Prof. Dr. med. Andreas Klos**

Institute for Medical Microbiology and Hospital Epidemiology, MHH

**Dr. rer. nat. Jürgen Mertsching**

Dept. of Biosafety, MHH

**Dr. rer. nat. Andreas Seiffert-Störiko**

Sanofi-Aventis Deutschland GmbH, Frankfurt/Main

@: [leman.andrea@mh-hannover.de](mailto:leman.andrea@mh-hannover.de)

Fax: +49-511-532-8580

Hannover Medical School (MHH)  
Andrea Leman  
Biosafety, OE 0014  
30623 Hannover

